{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:44:30Z","timestamp":1787010270490,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    Endometrioid borderline tumors (EBTs) and seromucinous borderline tumors (SMBTs) are rare ovarian neoplasms with distinct histologic features. However, the molecular profiles of EBTs and SMBTs remain incompletely characterized. We performed histologic evaluation and DNA\/RNA next-generation sequencing (NGS) using a 1425-gene pan-cancer panel on 11 EBTs and 10 SMBTs to define their mutational landscapes, conduct cross-comparisons between EBTs and SMBTs, and evaluate both against established profiles of endometrioid carcinoma and low-grade serous carcinoma. Histologically, EBTs showed adenofibromatous (64%) or intracystic (36%) growth patterns, with morule formation in 36% of cases. Aberrant nuclear \u03b2-catenin expression was observed in 73% of EBTs, significantly higher than in SMBTs (0%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.001). \u03b2-catenin abnormalities and morules were absent in SMBTs. 73% EBT and 60% SMBT were associated with endometriosis. Genetically, most EBTs harbored\n                    <jats:italic toggle=\"yes\">CTNNB1<\/jats:italic>\n                    mutations (73%) with additional alterations in\n                    <jats:italic toggle=\"yes\">KRAS<\/jats:italic>\n                    (36%),\n                    <jats:italic toggle=\"yes\">ARID1A<\/jats:italic>\n                    (27%),\n                    <jats:italic toggle=\"yes\">ATR<\/jats:italic>\n                    (27%),\n                    <jats:italic toggle=\"yes\">KMT2D<\/jats:italic>\n                    (27%),\n                    <jats:italic toggle=\"yes\">PIK3CA<\/jats:italic>\n                    (18%),\n                    <jats:italic toggle=\"yes\">PIK3R1<\/jats:italic>\n                    (18%),\n                    <jats:italic toggle=\"yes\">PTEN<\/jats:italic>\n                    (18%),\n                    <jats:italic toggle=\"yes\">AKT1<\/jats:italic>\n                    (18%),\n                    <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                    (18%), and several others (\u226418%). In contrast, SMBTs lacked\n                    <jats:italic toggle=\"yes\">CTNNB1<\/jats:italic>\n                    mutations but frequently had\n                    <jats:italic toggle=\"yes\">KRAS<\/jats:italic>\n                    (60%),\n                    <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                    (30%),\n                    <jats:italic toggle=\"yes\">PIK3CA<\/jats:italic>\n                    (20%),\n                    <jats:italic toggle=\"yes\">PIK3R1<\/jats:italic>\n                    (20%),\n                    <jats:italic toggle=\"yes\">PTEN<\/jats:italic>\n                    (20%),\n                    <jats:italic toggle=\"yes\">ATM<\/jats:italic>\n                    (20%),\n                    <jats:italic toggle=\"yes\">ZFHX3<\/jats:italic>\n                    (20%),\n                    <jats:italic toggle=\"yes\">AUTS2<\/jats:italic>\n                    (20%),\n                    <jats:italic toggle=\"yes\">CIC<\/jats:italic>\n                    (20%),\n                    <jats:italic toggle=\"yes\">FAT1<\/jats:italic>\n                    (20%), and\n                    <jats:italic toggle=\"yes\">PLAT<\/jats:italic>\n                    (20%) mutations, with 20% showing concurrent\n                    <jats:italic toggle=\"yes\">KRAS\/PIK3CA<\/jats:italic>\n                    mutations. Pathway analysis revealed predominant WNT\/\u03b2-catenin signaling in EBTs versus RAS-MEK-ERK pathway alterations in SMBTs resembling the seromucinous variant of ovarian endometrioid carcinoma, with additional involvement of PI3K-PTEN-AKT-mTOR and SWI\/SNF chromatin remodeling pathways in both. These findings demonstrate that EBTs and SMBTs possess distinct morphologic and molecular profiles, expanding the molecular characterization of early ovarian endometrioid-type neoplasms.\n                  <\/jats:p>","DOI":"10.1097\/pgp.0000000000001174","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:00:09Z","timestamp":1775152809000},"page":"253-261","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Endometrioid Versus Seromucinous Borderline Ovarian Tumors: Divergent Molecular Signatures and a Shared Role as Precursors to Endometrioid Carcinoma"],"prefix":"10.1097","volume":"45","author":[{"given":"Shuang","family":"Niu","sequence":"first","affiliation":[{"name":"Department of Pathology, UT Southwestern Medical Center"},{"name":"Department of Pathology, Parkland Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Molberg","sequence":"additional","affiliation":[{"name":"Department of Pathology, UT Southwestern Medical Center"},{"name":"Department of Pathology, Parkland Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Carrick","sequence":"additional","affiliation":[{"name":"Department of Pathology, UT Southwestern Medical Center"},{"name":"Department of Pathology, Parkland Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glorimar Rivera","family":"Colon","sequence":"additional","affiliation":[{"name":"Department of Pathology, UT Southwestern Medical Center"},{"name":"Department of Pathology, Baylor College of Medicine, Temple Campus, Temple, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Gwin","sequence":"additional","affiliation":[{"name":"Department of Pathology, UT Southwestern Medical Center"},{"name":"Department of Pathology, Parkland Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, UT Southwestern Medical Center"},{"name":"Department of Pathology, Parkland Hospital"},{"name":"Department of Obstetrics and Gynecology, UT Southwestern Medical Center"},{"name":"Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"SoRelle","sequence":"additional","affiliation":[{"name":"Department of Pathology, UT Southwestern Medical Center"},{"name":"Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego H.","family":"Castrillon","sequence":"additional","affiliation":[{"name":"Department of Pathology, UT Southwestern Medical Center"},{"name":"Department of Pathology, Parkland Hospital"},{"name":"Department of Obstetrics and Gynecology, UT Southwestern Medical Center"},{"name":"Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lucas","sequence":"additional","affiliation":[{"name":"Department of Pathology, UT Southwestern Medical Center"},{"name":"Department of Pathology, Parkland Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, UT Southwestern Medical Center"},{"name":"Department of Pathology, Parkland Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"R1-20260615","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/PAS.0000000000000812","article-title":"Morphologic reproducibility, genotyping, and immunohistochemical profiling do not support a category of seromucinous carcinoma of the ovary","volume":"41","author":"Rambau","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R2-20260615","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/path.1923","article-title":"High frequency of \u03b2-catenin mutations in borderline endometrioid tumours of the ovary","volume":"208","author":"Oliva","year":"2006","journal-title":"J Pathol"},{"key":"R3-20260615","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1038\/s41379-020-0611-3","article-title":"Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor","volume":"33","author":"Wu","year":"2020","journal-title":"Mod Pathol"},{"key":"R4-20260615","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2559.2010.03673.x","article-title":"Endocervical-like (M\u00fcllerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation","volume":"57","author":"Kim","year":"2010","journal-title":"Histopathology"},{"key":"R5-20260615","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.3390\/curroncol29050294","article-title":"Mutation profiles of ovarian seromucinous borderline tumors in Japanese patients","volume":"29","author":"Sasamori","year":"2022","journal-title":"Curr Oncol"},{"key":"R6-20260615","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/00000478-200309000-00009","article-title":"Ovarian endometrioid tumors of low malignant potential: a clinicopathologic study of 30 cases with comparison to well-differentiated endometrioid adenocarcinoma","volume":"27","author":"Roth","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R7-20260615","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00000478-200011000-00002","article-title":"A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary","volume":"24","author":"Bell","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"R8-20260615","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/PAS.0000000000001934","article-title":"Morules but not squamous differentiation are a reliable indicator of CTNNB1 (\u03b2-catenin) mutations in endometrial carcinoma and precancers","volume":"46","author":"Niu","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R9-20260615","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/01.pas.0000138178.10829.b8","article-title":"Endocervical-like mucinous borderline tumors of the ovary: a clinicopathologic analysis of 31 cases","volume":"28","author":"Rodriguez","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"R10-20260615","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/00000478-200212000-00001","article-title":"Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas","volume":"26","author":"Shappell","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"R11-20260615","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PAS.0000000000001810","article-title":"Reliable identification of endometrial precancers through combined Pax2, beta-Catenin, and Pten immunohistochemistry","volume":"46","author":"Aguilar","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R12-20260615","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/j.semdp.2021.12.001","article-title":"Histopathologic diagnosis of endometrial precancers: updates and future directions","volume":"39","author":"Chen","year":"2022","journal-title":"Semin Diagn Pathol"},{"key":"R13-20260615","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/PGP.0000000000001046","article-title":"\u03b2-catenin, PAX2, and PTEN aberrancy across the spectrum of endometrioid ovarian lesions","volume":"44","author":"Del Mundo","year":"2025","journal-title":"Int J Gynecol Pathol"},{"key":"R14-20260615","doi-asserted-by":"crossref","first-page":"e2100113","DOI":"10.1200\/CCI.21.00113","article-title":"ANSWER: annotation software for electronic reporting","volume":"6","author":"Raulerson","year":"2022","journal-title":"JCO Clin Cancer Inform"},{"key":"R15-20260615","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.5858\/arpa.2019-0476-RA","article-title":"Assembling and validating bioinformatic pipelines for next-generation sequencing clinical assays","volume":"144","author":"SoRelle","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"R16-20260615","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"R17-20260615","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Leon-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"R18-20260615","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ygyno.2016.12.015","article-title":"Molecular approaches for classifying endometrial carcinoma","volume":"145","author":"Piulats","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R19-20260615","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"key":"R20-20260615","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ijc.30573","article-title":"Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma","volume":"140","author":"Garcia-Sanz","year":"2017","journal-title":"Int J Cancer"},{"key":"R21-20260615","doi-asserted-by":"crossref","first-page":"djv249","DOI":"10.1093\/jnci\/djv249","article-title":"Patterns of CTCF and ZFHX3 mutation and associated outcomes in endometrial cancer","volume":"107","author":"Walker","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R22-20260615","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/path.5566","article-title":"Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma","volume":"253","author":"Li","year":"2021","journal-title":"J Pathol"},{"key":"R23-20260615","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.humpath.2017.07.003","article-title":"Clonal evolution in paired endometrial intraepithelial neoplasia\/atypical hyperplasia and endometrioid adenocarcinoma","volume":"67","author":"Russo","year":"2017","journal-title":"Hum Pathol"},{"key":"R24-20260615","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41379-019-0298-5","article-title":"Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia\/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma","volume":"32","author":"Chapel","year":"2019","journal-title":"Mod Pathol"},{"key":"R25-20260615","first-page":"20","article-title":"Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors","volume":"254","author":"Aguilar","year":"2021","journal-title":"J Pathol"},{"key":"R26-20260615","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1002\/cncr.32822","article-title":"Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma","volume":"126","author":"Russo","year":"2020","journal-title":"Cancer"},{"key":"R27-20260615","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2020.02.011","article-title":"An integrated molecular profile of endometrioid ovarian cancer","volume":"157","author":"Pierson","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R28-20260615","first-page":"2586","article-title":"Endometrioid ovarian carcinoma landscape: pathological and molecular characterization","volume":"18","author":"de Nonneville","year":"2024","journal-title":"Mol Oncol"},{"key":"R29-20260615","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1038\/s41467-020-18819-5","article-title":"Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome","volume":"11","author":"Hollis","year":"2020","journal-title":"Nat Commun"},{"key":"R30-20260615","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ygyno.2019.07.012","article-title":"Molecular profiling and molecular classification of endometrioid ovarian carcinomas","volume":"154","author":"Cybulska","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R31-20260615","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PAS.0000000000001810","article-title":"Reliable identification of endometrial precancers through combined Pax2, \u03b2-catenin, and Pten immunohistochemistry","volume":"46","author":"Aguilar","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R32-20260615","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/PAS.0000000000002076","article-title":"Utility of a PAX2, PTEN, and \u03b2-catenin panel in the diagnosis of atypical hyperplasia\/endometrioid intraepithelial neoplasia in endometrial polyps","volume":"47","author":"Lucas","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"R33-20260615","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J Pathol"},{"key":"R34-20260615","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol Oncol"},{"key":"R35-20260615","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-21-4183","article-title":"MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T19:01:33Z","timestamp":1781550093000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000001174","relation":{},"ISSN":["0277-1691","1538-7151"],"issn-type":[{"value":"0277-1691","type":"print"},{"value":"1538-7151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"2026-01-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}